Clinical Trials Logo

Accelerated Phase of Disease clinical trials

View clinical trials related to Accelerated Phase of Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT02210858 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Start date: May 2000
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and how well tipifarnib works in treating patients with chronic myeloid leukemia, chronic myelomonocytic leukemia, or undifferentiated myeloproliferative disorders. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01139970 Active, not recruiting - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Start date: May 21, 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studies the side effects and best dose of giving veliparib together with temozolomide in treating patients with acute leukemia. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with temozolomide may kill more cancer cells.

NCT ID: NCT00351975 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with azacitidine may kill more cancer cells.

NCT ID: NCT00003145 Active, not recruiting - Clinical trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Start date: August 1997
Phase: Phase 2
Study type: Interventional

This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and peripheral blood stem cell transplant followed by donor lymphocyte infusion in treating older patients with chronic myeloid leukemia. Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them (called graft-versus-tumor effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect.